If you have been reading about GW501516 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Typical form of reference material |
| Solubility | Low in water; soluble in DMSO | Used to prepare stock solutions |
| Typical storage | -20 °C, desiccated, protected from light | Common laboratory practice |
| Analytical method | LC-MS/MS | Detects parent compound and metabolites |
| Common test matrix | Urine or blood | Used in anti-doping analysis |
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Certain beta blockers, particularly oral propranolol and carvedilol as well as topical formulations of timolol and propranolol, are used in the treatment of rosacea, a disease that causes cosmetic redness of certain areas of the face.
In February 2020, the biosimilar Amsparity was approved for use in the European Union. In June 2020, the biosimilar Idacio was approved for use in Australia. In July 2020, adalimumab-fkjp (Hulio) was approved for use in the United States. In August 2020, the biosimilar Cadalimab was launched in India by Cadila Pharmaceuticals. In October 2020, Idacio was approved for medical use in Canada. In November 2020, Amgevita, Hulio, and Hyrimoz were approved for medical use in Canada. In February 2021, Yuflyma was approved for medical use in the European Union. In January 2021, Abrilada was approved for medical use in Canada. In November 2021, the biosimilars Libmyris and Hukyndra were approved for medical use in the European Union. In December 2021, adalimumab-aqvh (Yusimry) was approved for medical use in the United States. In December 2021, Yuflyma was approved for medical use in Canada. In January 2022, Simlandi was approved for medical use in Canada. In December 2022, Adalimumab-aacf (Idacio) was approved for medical use in the United States. In January 2023, the CHMP recommended that the high-concentration 100mg/ml Hyrimoz biosimilar be granted a pan-European marketing authorization for all indications covered by the reference medicine, including Crohn's disease, plaque psoriasis, ulcerative colitis, rheumatoid arthritis and uveitis. In January 2023, Simlandi was approved for medical use in Saudi Arabia. In May 2023, Adalimumab-aaty (Yuflyma) was approved for medical use in the United States.
In March 2025, Jeffrey Goldberg, the editor-in-chief of The Atlantic, reported that he had been accidentally included by Mike Waltz in a Signal group chat where Hegseth shared information about attacks in Yemen hours before they occurred. The discussions involved US officials, including Vance and secretary of state Marco Rubio. According to The New York Times, several officials with the Department of Defense expressed shock at the incident, while various former national security officials noted the potential for espionage amid ongoing efforts by China to obtain telecommunications records. A spokesperson for the National Security Council confirmed Goldberg's report and the authenticity of the messages. Hegseth rejected that war plans were shared and called Goldberg "deceitful" and a "discredited so-called journalist". Director of National Intelligence Tulsi Gabbard said no classified information was shared and CIA director John Ratcliffe said Signal was authorized for the group chat. The incident distressed Hegseth, who threatened to use a polygraph on Christopher W. Grady, the acting chairman of the Joint Chiefs of Staff. Goldberg later published most of the Signal chat. The chat showed that Hegseth posted information including the launch times of F-18 aircraft, MQ-9 drones and Tomahawk missiles, as well as the time when the F-18 aircraft would reach their targets, and the time when the bombs would land. Hegseth commented on the chat, writing that there were: "No names. No targets. No locations. No units. No routes. No sources. No methods. And no classified information".
Sources: en.wikipedia.org
In prehistoric and protohistoric times, over a period of approximately 500,000 years, the area of present-day Poland was intermittently inhabited by members of the genus Homo. The earliest evidence of Homo erectus activity in the form of microlith artifacts was discovered at Trzebnica, in Lower Silesia. It remains the oldest archeological site in the country, dating back to the Lower Paleolithic period of the Stone Age. The southern regions of Poland were subsequently penetrated by sporadic groups of Neanderthals. Their presence was confirmed by the stone tools unearthed in caves of the Kraków-Częstochowa Upland, a limestone formation with hills, cliffs and valleys that came to be known as the Polish Jura. The arrival of Homo sapiens and anatomically modern humans coincided with the climatic discontinuity at the end of the Last Glacial Period (Weichselian glaciation) around 10,000 BC, when Poland became warmer and habitable. It allowed various groups of early humans to pass the Sudeten Mountains through the Moravian Gate and the Kłodzko Valley into Lower Silesia. The Neolithic period ushered in the Linear Pottery culture, whose founders belonged to the Danubian culture and migrated from the Danube River area beginning about 5500 BC. This culture was distinguished by the establishment of the first settled agricultural communities in modern Polish territory. Later, between about 4400 and 2000 BC, the native post-Mesolithic populations would also adopt and further develop the agricultural way of life. Excavations indicated broad-ranging development in the New Stone Age.
== Definition == Distribution is fundamentally concerned with ensuring that products reach target customers in the most direct and cost-efficient manner. In the case of services, distribution is principally concerned with access. Although distribution, as a concept, is relatively simple, in practice Distribution management may involve a diverse range of activities and disciplines including detailed logistics, transportation, warehousing, storage, inventory management as well as channel management, including selection of channel members and rewarding distributors.
The importation of mephedrone into the UK was banned on 29 March 2010. The next day, the ACMD in the UK published a report on the cathinones, including mephedrone, and recommended they be classified as Class B drugs. On 7 April 2010, the Misuse of Drugs Act 1971 (Amendment) Order 2010 was passed by parliament, making mephedrone and other substituted cathinones, Class B drugs from 16 April 2010. Prior to the ban taking effect, mephedrone was not covered by the Misuse of Drugs Act 1971. It was, though, an offence under the Medicines Act to sell it for human consumption, so it was often sold as "plant food" or "bath salts", although it has no use as these products; this, too, was possibly illegal under the Trade Descriptions Act 1968. In the US, similar descriptions have been used to describe mephedrone, as well as methylenedioxypyrovalerone (MDPV). In May 2010, the Republic of Ireland made mephedrone illegal, followed by Belgium, Italy, Lithuania, France and Norway in June and Russia in July. In August 2010, Austria and Poland made it illegal and China announced it would be illegal as of 1 September 2010. Mephedrone had been reported to be used in Singapore in February 2010, but it was made illegal in November 2010. In December 2010, following the advice of the EMCDDA, mephedrone was made illegal throughout the EU, a move Switzerland also made shortly afterwards. Countries which have not already banned it, such as the Netherlands, Greece and Portugal, will need to change legislation to comply with the EU ruling.
Sources: en.wikipedia.org
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.
PPARδ is a nuclear receptor that regulates genes linked to fatty acid oxidation and energy metabolism. Activation can alter lipid handling and energy use in experimental models. The full range of effects in humans is still under study.
The solid compound is generally stable when kept cold, dry, and protected from light. Solutions may degrade faster, so laboratory protocols often specify fresh preparation or cold storage. Stability can depend on solvent, concentration, and container.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.